Medication adherence during laboratory workup for primary aldosteronism: pilot study

References

• RossiGPBerniniGCaliumiCPAPY Study InvestigatorsA prospective study of the prevalence of primary aldosteronism in 1 125 hypertensive patientsJ Am Coll Cardiol200648112293230017161262
   PubMed Web of Science ®Google Scholar
• FunderJWCareyRMManteroFThe management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guidelineJ Clin Endocrinol Metab201610151889191626934393
   PubMed Web of Science ®Google Scholar
• LeungAADaskalopoulouSSDasguptaKHypertension CanadaHypertension Canada’s 2017 Guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adultsCan J Cardiol201733555757628449828
   PubMed Web of Science ®Google Scholar
• DouillardCHouillierPNussbergerJGirerdXSFE/SFHTA/AFCE consensus on primary aldosteronism, part 2: first diagnostic stepsAnn Endocrinol (Paris)201677319220127177498
   PubMed Web of Science ®Google Scholar
• HamdidoucheIJullienVBoutouyriePBillaudEAziziMLaurentSDrug adherence in hypertension: from methodological issues to cardiovascular outcomesJ Hypertens20173561133114428306634
   PubMed Web of Science ®Google Scholar
• PandeyARazaFVelascoAComparison of Morisky Medication Adherence Scale with therapeutic drug monitoring in apparent treatment-resistant hypertensionJ Am Soc Hypertens201596420426.e226051923
   PubMed Web of Science ®Google Scholar
• StevensPELevinABilousRWKidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group MembersEvaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guidelineAnn Intern Med20131581182583023732715
   PubMed Web of Science ®Google Scholar
• VogelmeierCFCrinerGJMartinezFJGlobal strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summaryAm J Respir Crit Care Med2017195555758228128970
   PubMed Web of Science ®Google Scholar
• LeveyASStevensLAEstimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictionsAm J Kidney Dis201055462262720338463
   PubMed Web of Science ®Google Scholar
• MaurerHHMulti-analyte procedures for screening for and quantification of drugs in blood, plasma, or serum by liquid chromatography-single stage or tandem mass spectrometry (LC-MS or LC-MS/MS) relevant to clinical and forensic toxicologyClin Biochem200538431031815766732
   PubMed Web of Science ®Google Scholar
• LouisWJWorkmanBSConwayELSingle-dose and steady-state pharmacokinetics and pharmacodynamics of perindopril in hypertensive subjectsJ Cardiovasc Pharmacol19922035055111279299
   PubMed Web of Science ®Google Scholar
• Medicines Evaluation Board in the NetherlandsUtrecht, NL, 2012 Public assessment report: candesartan cilexetil LincosaEU procedure number NL/H/2048/002/004/DC Available from: https://db.cbg-meb.nl/Pars/h107585.pdfAccessed July 01, 2018
   Google Scholar
• MeinekeIFeltkampHHögemannAGundert-RemyUPharmacokinetics and pharmacodynamics of candesartan after administration of its pro-drug candesartan cilexetil in patients with mild to moderate essential hypertension-a population analysisEur J Clin Pharmacol1997533–42212289476035
   PubMed Web of Science ®Google Scholar
• MarinoMRLangenbacherKFordNFUdermanHDPharmacokinetics and pharmacodynamics of irbesartan in healthy subjectsJ Clin Pharmacol19983832462559549663
   PubMed Web of Science ®Google Scholar
• SchwochoLRMasonsonHNPharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjectsJ Clin Pharmacol200141551552711361048
   PubMed Web of Science ®Google Scholar
• MüllerPFleschGde GasparoMGaspariniMHowaldHPharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjectsEur J Clin Pharmacol19975264414499342579
   PubMed Web of Science ®Google Scholar
• ChenCLDesai-KriegerDOrtizSKerolousMWrightHMGhahramaniPA single-center, open-label, 3-way crossover trial to determine the pharmacokinetic and pharmacodynamic interaction between nebivolol and valsartan in healthy volunteers at steady stateAm J Ther2015225e130e14025853236
   PubMed Web of Science ®Google Scholar
• StangierJSuCAPharmacokinetics of repeated oral doses of amlodipine and amlodipine plus telmisartan in healthy volunteersJ Clin Pharmacol20004012 Pt 11347135411185633
   PubMed Web of Science ®Google Scholar
• BainbridgeADHerlihyOMeredithPAElliottHLA comparative assessment of amlodipine and felodipine ER: pharmacokinetic and pharmacodynamic indicesEur J Clin Pharmacol19934554254308112371
   PubMed Web of Science ®Google Scholar
• Swissmedic, Schweizerisches Heilmittelinstitut, Bern, SwitzerlandPublic product information: Lercanidipin Sandoz® Available from: www.swissmedicinfo.chAccessed July 01, 2018
   Google Scholar
• BarchielliMDolfiniEFarinaPClinical Pharmacokinetics of LercanidipineJ Cardiovasc Pharmacol199729Suppl 2S1S15
   Google Scholar
• KamaliFHowesAThomasSHFordGASnoeckEA pharmacokinetic and pharmacodynamic interaction study between nebivolol and the H2-receptor antagonists cimetidine and ranitidineBr J Clin Pharmacol19974322012049131955
   PubMed Web of Science ®Google Scholar
• WellingPGPharmacokinetics of the thiazide diureticsBiopharm Drug Dispos1986765015353828483
   PubMed Web of Science ®Google Scholar
• KendallMJMetoprolol-controlled release, zero order kineticsJ Clin Pharm Ther19891431591792668307
   PubMed Web of Science ®Google Scholar
• StrauchBPetrákOZelinkaTPrecise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysisJ Hypertens201331122455246124220593
   PubMed Web of Science ®Google Scholar
• McNaughtonCDBrownNJRothmanRLSystolic blood pressure and biochemical assessment of adherence: a cross-sectional analysis in the emergency departmentHypertension201770230731428652467
   PubMed Web of Science ®Google Scholar
• HamdidoucheIJullienVBoutouyriePBillaudEAziziMLaurentSRoutine urinary detection of antihypertensive drugs for systematic evaluation of adherence to treatment in hypertensive patientsJ Hypertens20173591891189828505066
   PubMed Web of Science ®Google Scholar
• JungOGechterJLWunderCResistant hypertension? Assessment of adherence by toxicological urine analysisJ Hypertens201331476677423337469
   PubMed Web of Science ®Google Scholar
• GuptaPPatelPŠtrauchBBiochemical screening for nonadherence is associated with blood pressure reduction and improvement in adherenceHypertension20177051042104828847892
   PubMed Web of Science ®Google Scholar
• CeralJHabrdovaVVorisekVBimaMPelouchRSolarMDifficult-to-control arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapyHypertens Res2011341879020882030
   PubMed Web of Science ®Google Scholar
• RyanTPMorrisonRDSutherlandJJMedication adherence, medical record accuracy, and medication exposure in real-world patients using comprehensive medication monitoringPLoS One2017129e018547128957369
   PubMed Web of Science ®Google Scholar
• BurnierMDrug adherence in hypertensionPharmacol Res2017125Pt B14214928870498
   PubMed Web of Science ®Google Scholar